Gender affects the curative effect of rituximab for treatment of diffuse large B cell lymphoma
10.3969/j.issn.1006-5725.2014.24.023
- VernacularTitle:性别影响利妥昔单抗治疗弥漫大B细胞淋巴瘤
- Author:
Yang LIU
;
Jinghua LIU
;
Yanqin LIU
;
Jigang WANG
;
Ying BAI
;
Fan ZHOU
- Publication Type:Journal Article
- Keywords:
Diffuse large B cell lymphoma;
Rituximab;
Gender;
Progression-free survival
- From:
The Journal of Practical Medicine
2014;(24):3946-3948
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of gender on the curative effect of rituximab for the treatment of diffuse large B cell lymphoma with five-year progression-free survival. Methods The clinical and laboratorial data of 155 diffuse large B cell lymphoma patients from January 2003 to January 2011 were retrospectively analyzed. The patients were divided it into R-CHOP group and CHOP group according to if rituximab was used, and then subdivided based on their gender into R-CHOP-M, R-CHOP-F groups and CHOP-M, CHOP-F groups, respectively. Kaplan-Meier survival curve was plotted for the progression-free survival. Results The five-year progression-free survival rate in the R-CHOP group was higher than the CHOP group, and the rate of R-CHOP-F group was higher than R-CHOP-M group, but there were no significant differences between the CHOP-M group and the CHOP-F group. The rate of the R-CHOP-M group was a little bit higher than the CHOP-M group with no statistical significance. The rate of the R-CHOP-F group was higher than CHOP-F group. Conclusion Rituximab is beneficial for female than for male, which may contribute to the adjustment of drug doses if a male is treated with rituximab.
